Humans have two nearly identical copies of the Survival Motor Neuron (SMN) gene, SMN1 and SMN2. In spinal muscular atrophy (SMA), SMN2 is not able to compensate for the loss of SMN1 due to exclusion of...
Spinal muscular atrophy (SMA) is one of the leading genetic diseases of children and infants. SMA is caused by deletions or mutations of Survival Motor Neuron 1 (SMN1) gene. SMN2, a nearly identical copy of SMN1, cannot...
A "real world" trial of Dificid (fidaxomicin) from Astellas/Cubist Pharma was carried out at St Georges Hospital London which showed...
Teva Pharmaceutical Industries announced that results from the 52-week, multicenter, randomized, double-blind, parallel group study evaluating monthly or quarterly Ajovy (fremanezumab-vfrm) injection in adults with chronic migraine (CM) or episodic migraine (EM), were published online ahead of print in Neurology.
Spinal muscular atrophy (SMA) is a genetic disease caused by mutation or deletion of the survival of motor neuron 1 (SMN1) gene. A paralogous gene in humans, SMN2, produces low, insufficient levels of functional SMN...
Eton Pharmaceuticals, Inc reported that its partner, Bausch & Lomb, has not yet received a communication from the FDA regarding its decision on the review of EM 100. EM 100’s Generic Drug User Fee Act (GDUFA) target action date was August 10th